Overview of the latest treatments for castration-resistant prostate cancer

被引：51
作者：
Bishr, Mohamed [1 ]
Saad, Fred [2 ]
机构：
[1] Ctr Hosp Univ Montreal, Ctr Rech, Montreal, PQ H2L 4M1, Canada
[2] Ctr Hosp Univ Montreal, Div Urol, 1560 Sherbrooke East, Montreal, PQ H2L 4M1, Canada
来源：
NATURE REVIEWS UROLOGY | 2013年 / 10卷 / 09期
关键词：
ANDROGEN-DEPRIVATION THERAPY; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; BONE-MINERAL DENSITY; ZOLEDRONIC ACID; PHASE-II; ANTIANDROGEN WITHDRAWAL; 2ND-LINE CHEMOTHERAPY; SURVIVAL ANALYSIS; DOUBLE-BLIND;
D O I：
10.1038/nrurol.2013.137
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Over the past few years, we have developed an increased understanding of the molecular mechanisms that underlie prostate cancer progression and castration resistance and expanded our repertoire of therapeutic options for castration-resistant prostate cancer (CRPC). Four new agents (cabazitaxel, abiraterone acetate, enzalutamide, and radium-233) have been shown to prolong overall survival in patients with CRPC in the postchemotherapy setting. Targeting the androgen receptor pathway continues to have an important role in the treatment of CRPC, with abiraterone acetate and enzalutamide being the most exciting developments. Cabazitaxel is now considered the standard-of-care second-line chemotherapy for men with metastatic CRPC (mCRPC). Bone-targeted therapy is an active area of research, with denosumab being the first bone-targeted agent able to significantly delay the appearance of bone metastases in patients with CRPC and radium-223 being the first radiopharmaceutical agent to improve survival in patients with mCRPC.
引用
收藏
页码：522 / 528
页数：7
相关论文
共 70 条
[1]   Expanding Treatment Options for Metastatic Prostate Cancer [J].
Antonarakis, Emmanuel S. ;
Eisenberger, Mario A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :2055-2058
[2]   Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells [J].
Asim, M. ;
Siddiqui, I. A. ;
Hafeez, B. B. ;
Baniahmad, A. ;
Mukhtar, H. .
ONCOGENE, 2008, 27 (25) :3596-3604
[3]   Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa [J].
Berthold, D. R. ;
Pond, G. R. ;
de Wit, R. ;
Eisenberger, M. ;
Tannock, I. F. .
ANNALS OF ONCOLOGY, 2008, 19 (10) :1749-1753
[4]   Osteoclast differentiation and activation [J].
Boyle, WJ ;
Simonet, WS ;
Lacey, DL .
NATURE, 2003, 423 (6937) :337-342
[5]   Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer [J].
Calcagno, Fabien ;
Nguyen, Thierry ;
Dobi, Erion ;
Villanueva, Cristian ;
Curtit, Elsa ;
Kim, Stefano ;
Montcuquet, Philippe ;
Kleinclauss, Francois ;
Pivot, Xavier ;
Thiery-Vuillemin, Antoine .
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2013, 7 :1-12
[6]   CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy [J].
Chambers, CA ;
Kuhns, MS ;
Egen, JG ;
Allison, JP .
ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :565-594
[7]   Low-dose diethylstilbestrol for the treatment of advanced prostate cancer [J].
Clemons, Julia ;
Glode, L. Michael ;
Gao, Dexiang ;
Flaig, Thomas W. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (02) :198-204
[8]   Safety of intravenous and oral bisphosphonates and compliance with dosing regimens [J].
Conte, P ;
Guarneri, V .
ONCOLOGIST, 2004, 9 :28-37
[9]   ESTROGENS IN THE TREATMENT OF PROSTATE-CANCER [J].
COX, RL ;
CRAWFORD, ED .
JOURNAL OF UROLOGY, 1995, 154 (06) :1991-1998
[10]   Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].
de Bono, Johann Sebastian ;
Oudard, Stephane ;
Ozguroglu, Mustafa ;
Hansen, Steinbjorn ;
Machiels, Jean-Pascal ;
Kocak, Ivo ;
Gravis, Gwenaelle ;
Bodrogi, Istvan ;
Mackenzie, Mary J. ;
Shen, Liji ;
Roessner, Martin ;
Gupta, Sunil ;
Sartor, A. Oliver .
LANCET, 2010, 376 (9747) :1147-1154
1234567